NEW YORK, January 30, 2017 /PRNewswire/ --
Stock-Callers.com has initiated reports coverage on these four Biotech
Last Friday, Dublin, Ireland headquartered Jazz Pharmaceuticals PLC's stock climbed 0.02%, to close the day at $119.48. A total volume of 419,971 shares was traded. The Company's shares have advanced 6.49% in the last month, 1.63% in the previous three months, and 9.58% on an YTD basis. The stock is trading 7.80% above its 50-day moving average. Additionally, shares of Jazz Pharma, which identifies, develops, and commercializes pharmaceutical products for various medical needs in the US, Europe, and internationally, have a Relative Strength Index (RSI) of 56.06.
On January 17th, 2017, Jazz Pharmaceuticals announced that the first patient has been enrolled in a Phase-3 clinical trial comparing the efficacy and safety of defibrotide versus best supportive care in the prevention of hepatic veno-occlusive disease (VOD) in adult and pediatric patients undergoing hematopoietic stem cell transplant who are at high risk or at very high risk of developing VOD. The defibrotide clinical trial will be conducted across approximately 100 medical centers in the US, Canada, Asia/Pacific and countries in the European Union. The free research report on JAZZ is available at:
Shares in Cambridge, Massachusetts headquartered Infinity Pharmaceuticals Inc. finished Friday's session flat at $2.10. The stock recorded a trading volume of 846,513 shares. The Company's shares have surged 41.89% in the last month, 62.79% over the previous three months, and 55.56% since the start of this year. The stock is trading above its 50-day moving average by 48.12%. Furthermore, shares of Infinity Pharma, which discovers, develops, and delivers medicines to patients with difficult-to-treat diseases, have an RSI of 72.42.
On January 20th, 2017, Infinity Pharma presented preclinical data for IPI-549, an oral immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase-gamma (PI3K-gamma). Preclinical data showed that IPI-549 is able to help overcome resistance to checkpoint inhibition by remodeling the immune-suppressive tumor microenvironment primarily through its effects on myeloid cells, a type of cell considered to be involved in suppressing immune response against tumors. Initial Phase-1 monotherapy data from nine patients with advanced solid tumors were also summarized and showed that the safety, pharmacokinetics and pharmacodynamics of IPI-549 monotherapy treatment appeared favorable. IPI-549 is believed to be the only PI3K-gamma inhibitor in clinical development. The complimentary report on INFI can be downloaded at:
Ardsley, New York headquartered Acorda Therapeutics Inc.'s stock finished 3.58% lower at $20.20 last Friday at the close. A total volume of 753,165 shares was traded, which was above their three months average volume of 605,590 shares. The Company's shares have advanced 10.08% in the past month, 2.28% in the previous three months, and 7.45% on an YTD basis. The stock is trading below its 50-day moving average by 1.23%. Additionally, shares of Acorda Therapeutics, which identifies, develops, and commercializes novel therapies for neurological disorders in the US, have an RSI of 47.38.
On January 09th, 2017, Acorda Therapeutics reported AMPYRA® (dalfampridine) extended release tablets, 10 mg net sales for Q4 2016 of $132 million, while full-year 2016 net sales were $493 million, an increase of approximately 13% from full year 2015. The Company provided full year 2017 guidance for AMPYRA net sales of $535 million-$545 million, research and development expense of $185 million-$195 million, and sales, general, and administrative expense of $195 million-$205 million. Visit us today and download our complete research report on ACOR for free at:
Novato, California headquartered Ultragenyx Pharmaceutical Inc.'s shares ended the session 0.71% higher at $69.15. The stock recorded a trading volume of 184,061 shares. The Company's shares have advanced 9.54% over the previous three months, and are trading 3.50% above their 200-day moving average. Moreover, shares of Ultragenyx Pharma, which focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the US, have an RSI of 40.95.
On January 05th, 2017, Ultragenyx Pharmaceutical and Kyowa Kirin International PLC, a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd announced that the European Medicines Agency has accepted for review the Marketing Authorization Application (MAA) for KRN23 for the treatment of X-linked hypophosphatemia. The MAA was filed and accepted in late 2016, and an opinion from the Committee for Medicinal Products for Human Use is expected in H2 2017. Get free access to your technical report on RARE at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...
Hashimoto's thyroiditis is an autoimmune disorder of the thyroid causing hypothyroidism. Synthetic ...
Strokes occur when blood flow to an area of the brain is cut off. It is imperitive to detect the ...View All